Developing a new treatment targeting LCN2 for lung cancer
Targeting LCN2, a novel therapy for lung cancer
This study is looking at a new way to help people with KRAS-driven non-small cell lung cancer by targeting a protein called Lipocalin 2, which might help tumors hide from the immune system, to see if we can make current treatments work better and improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11040380 on NIH RePORTER |
What this research studies
This research focuses on a novel therapy for KRAS-driven non-small cell lung cancer (NSCLC), which is known for its aggressive nature and resistance to standard treatments. The study investigates the role of Lipocalin 2 (LCN2), a protein that may help tumors evade the immune system, and aims to develop strategies to inhibit its effects. By using advanced techniques like CRISPR/Cas9, researchers will explore how targeting LCN2 can enhance the effectiveness of existing cancer therapies and improve patient outcomes. The goal is to identify new treatment options that can work alongside current therapies to better combat this challenging form of lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with KRAS-driven non-small cell lung cancer who have not responded well to standard therapies.
Not a fit: Patients with lung cancer that does not have KRAS mutations or those who have already responded well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with KRAS-driven lung cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting immunomodulatory molecules like LCN2, suggesting that this approach could be a viable new strategy in cancer treatment.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Papagiannakopoulos, Thales — New York University School of Medicine
- Study coordinator: Papagiannakopoulos, Thales
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.